文献速递泌尿男性生殖肿瘤

他喹莫德维持治疗转移性去势抵抗性前列腺癌的随机双盲安慰剂对照II期研究

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.
PubMed 文献 · Ann Oncol · 2017-01-01

本II期研究评估他喹莫德维持治疗对一线多西他赛化疗期间未进展的转移性去势抵抗性前列腺癌患者的疗效。144例患者随机接受他喹莫德(0.25-1.0 mg/日口服)或安慰剂,主要终点为影像学无进展生存期(rPFS)。他喹莫德组中位rPFS为31.7周,安慰剂组为22.7周(HR 0.6,90%CI 0.4-0.9,P=0.0162),维持治疗显著降低rPFS风险40%。

要点

  • 他喹莫德维持治疗较安慰剂显著延长rPFS(中位31.7 vs 22.7周,HR 0.6)。
  • 严重TEAE(NCI-CTC 3-5级)发生率他喹莫德组50.7% vs 安慰剂组27.1%。
  • 总生存未达到,截止日期仅14例死亡。

核心结论

  • 在转移性去势抵抗性前列腺癌患者中,一线多西他赛化疗后给予他喹莫德维持治疗显著降低rPFS风险40%。
  • 他喹莫德组与安慰剂组在症状性PFS、PFS 2、BPI评分、FACT-P评分或EQ-5D方面无统计学显著差异。

研究设计与样本

  • 随机、双盲、安慰剂对照II期研究,患者按1:1随机接受他喹莫德(0.25-1.0 mg/日口服)或安慰剂。
  • 共筛查219例患者,随机144例;主要终点为影像学无进展生存期(rPFS)。

主要发现

  • 他喹莫德组中位治疗持续时间18.7周(范围0.6-102.7周),安慰剂组19.2周(范围0.4-80.0周)。
  • 他喹莫德组中位rPFS为31.7周(90%CI 24.3-53.7),安慰剂组为22.7周(90%CI 16.1-25.9),HR 0.6(90%CI 0.4-0.9),P=0.0162。
  • 中位OS未达到,截止日期仅发生14例死亡。
  • 症状性PFS、PFS 2、BPI评分、FACT-P评分或EQ-5D在治疗组间无统计学显著差异。
  • 任何TEAE发生率他喹莫德组97.2% vs 安慰剂组94.3%,严重TEAE(NCI-CTC 3-5级)发生率他喹莫德组50.7% vs 安慰剂组27.1%。

临床怎么用

  • 对于一线多西他赛化疗期间未进展的转移性去势抵抗性前列腺癌患者,可考虑他喹莫德维持治疗以延长rPFS。
  • 他喹莫德维持治疗时需注意严重TEAE发生率较高(50.7% vs 27.1%)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This phase II study was conducted to assess clinical efficacy of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer not progressing during first-line docetaxel-based therapy. PATIENTS AND METHODS: Patients were randomly assigned (1 : 1) to receive tasquinimod (0.25-1.0 mg/day orally) or placebo. The primary end point was radiologic progression-free survival (rPFS); secondary efficacy end points included: overall survival (OS); PFS on next-line therapy (PFS 2) and symptomatic PFS, assessed using the Brief Pain Inventory (BPI) questionnaire and analgesic use. Quality of life was measured by the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire and by the EuroQol-5 Dimension Quality of Life Instrument (EQ-5D). Adverse events were recorded. RESULTS: A total of 219 patients were screened and 144 patients randomized. The median duration of treatment was 18.7 weeks (range 0.6-102.7 weeks) for the tasquinimod arm and 19.2 weeks (range 0.4-80.0 weeks) for the placebo arm. Median (90% CI) rPFS was 31.7 (24.3-53.7) and 22.7 (16.1-25.9) weeks in the tasquinimod and placebo arms, respectively [HR (90% CI) 0.6 (0.4-0.9), P = 0.0162]. The median OS was not reached because only 14 deaths occurred by the cut-off date. No statistically significant differences between treatment arms were noted for symptomatic PFS, PFS 2, BPI score, FACT-P score, or EQ-5D. The incidence of any treatment emergent adverse event (TEAE) was similar in the tasquinimod and placebo arms (97.2% versus 94.3%, respectively), whereas severe TEAEs (NCI-CTC Grade 3-5) incidence was higher in the tasquinimod group (50.7% versus 27.1%). CONCLUSIONS: Randomized trials testing new drugs as maintenance can be successfully conducted after chemotherapy in castrate-resistant prostate cancer. Maintenance tasquinimod therapy significantly reduced the risk of rPFS by 40%. CLINICALTRIALS: gov identifier NCT01732549.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Fizazi K, Ulys A, Sengeløv L, et al. A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy. Ann Oncol. 2017. PMID: 29059273. doi:10.1093/annonc/mdx487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。